◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › V › VCEL

Vericel Corp Ord (VCEL) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · BIOTECHNOLOGY · DATA UPDATED 2026-09-06

Vericel Corp Ord (VCEL) operates in the BIOTECHNOLOGY industry and is headquartered in Burlington, United States with about 398 employees. Its market capitalization is roughly $2 billion. In the fiscal year ended 2025-12-31, VCEL reported $276M in revenue and $17M in net income.

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America.

Interactive charts & full statements → Open the VCEL valuation workbench →

VCEL Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Revenue	$306M	$276M	$237M	$198M	$164M	$156M	$124M	$118M	$91M	$64M	$54M	$51M	$29M	$0M	$0M	$0M	$0M	$0M	$1M	$1M	$1M
Gross Profit	$228M	$206M	$172M	$136M	$110M	$106M	$84M	$80M	$59M	$34M	$26M	$25M	$12M	$0M	$0M	$0M	$0M	$0M	$0M	$1M	$1M
Gross Margin %	74.5%	74.4%	72.5%	68.6%	66.8%	67.9%	67.8%	68.1%	64.6%	52.5%	47.9%	48.3%	40.0%	79.0%	71.4%	77.8%	61.8%	38.5%	89.3%	95.8%	98.7%
Operating Income (EBIT)	$17M	$11M	$5M	($6M)	($17M)	($8M)	$2M	($11M)	($4M)	($15M)	($19M)	($17M)	($24M)	($21M)	($34M)	($29M)	($18M)	($16M)	($21M)	($19M)	($18M)
Operating Margin %	5.6%	4.0%	1.9%	-3.3%	-10.4%	-5.0%	1.9%	-9.6%	-4.3%	-23.4%	-35.4%	-32.6%	-81.7%	-110336.8%	-160761.9%	-161333.3%	-20004.5%	-8884.1%	-4064.9%	-2842.2%	-2054.8%
Net Income	$24M	$17M	$10M	($3M)	($17M)	($7M)	$3M	($10M)	($8M)	($17M)	($20M)	($16M)	($20M)	($16M)	($29M)	($20M)	($18M)	($16M)	($20M)	($18M)	($16M)
Net Margin %	7.8%	6.0%	4.4%	-1.6%	-10.2%	-4.8%	2.3%	-8.2%	-9.0%	-27.0%	-36.0%	-31.9%	-69.2%	-82221.1%	-140352.4%	-109266.7%	-19920.2%	-8761.5%	-3856.9%	-2568.5%	-1909.0%
EBITDA	$39M	$30M	$17M	$3M	($12M)	($5M)	$5M	($8M)	($5M)	($15M)	($17M)	($15M)	($19M)	($15M)	($29M)	($19M)	($30M)	($18M)	($15M)	($20M)	($19M)
Earnings Per Share (EPS)	$0.47	$0.32	$0.20	$-0.07	$-0.35	$-0.16	$0.06	$-0.22	$-0.20	$-0.52	$-0.85	$-0.69	$-1.71	$-5.18	$-14.31	$-10.19	$-14.34	$-17.84	$-24.95	$-23.55	$-16.00
Shares Outstanding (M)	51M	52M	52M	48M	47M	46M	47M	44M	40M	33M	23M	24M	12M	3M	2M	2M	1M	1M	1M	1M	1M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

VCEL Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	$77M	$68M	$93M	$68M	$63M	$53M	$75M	$58M
Gross Profit	$56M	$49M	$73M	$50M	$47M	$36M	$58M	$42M
Gross Margin %	72.8%	72.0%	78.7%	73.5%	73.7%	69.0%	77.6%	71.9%
Operating Income (EBIT)	$0M	($8M)	$22M	$3M	($2M)	($13M)	$18M	($2M)
Operating Margin %	0.6%	-11.8%	24.1%	5.1%	-3.2%	-24.3%	24.5%	-4.3%
Net Income	$2M	($6M)	$23M	$5M	($1M)	($11M)	$20M	($1M)
Net Margin %	2.9%	-9.2%	25.0%	7.5%	-0.9%	-21.4%	26.3%	-1.6%
EBITDA	$6M	($3M)	$28M	$8M	$2M	($8M)	$22M	$1M
Earnings Per Share (EPS)	$0.04	$-0.12	$0.45	$0.10	$-0.01	$-0.23	$0.38	$-0.02
Shares Outstanding (M)	51M	51M	52M	52M	50M	50M	52M	49M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

VCEL Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Cash from Operations (CFO)	$69M	$52M	$58M	$35M	$18M	$29M	$18M	($7M)	$0M	($13M)	($20M)	($13M)	($25M)	($20M)	($30M)	($24M)	($15M)	($14M)	($20M)	($15M)	($14M)
Capital Expenditures (CapEx)	$20M	$27M	$64M	$28M	$8M	$8M	$3M	$3M	$3M	$2M	$1M	$2M	$1M	$0M	$0M	$1M	$0M	$0M	$0M	$1M	$1M
Free Cash Flow (FCF)	$49M	$25M	($6M)	$8M	$10M	$21M	$15M	($10M)	($3M)	($15M)	($21M)	($16M)	($26M)	($20M)	($30M)	($26M)	($15M)	($14M)	($20M)	($16M)	($14M)
FCF Margin %	16.0%	9.0%	-2.5%	4.0%	6.1%	13.5%	12.0%	-8.3%	-3.4%	-23.0%	-39.2%	-30.8%	-91.1%	-105173.7%	-141990.5%	-141794.4%	-17084.3%	-7604.4%	-3782.0%	-2319.7%	-1657.8%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

VCEL Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	$16M	$16M	$15M	$22M	$8M	$7M	$22M	$10M
Capital Expenditures (CapEx)	$2M	$1M	$14M	$3M	$14M	$14M	$14M	$31M
Free Cash Flow (FCF)	$14M	$15M	$1M	$19M	($6M)	($8M)	$8M	($21M)
FCF Margin %	18.4%	22.1%	0.9%	28.8%	-9.5%	-14.5%	11.2%	-35.6%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

VCEL Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Assets	$503M	$488M	$433M	$354M	$273M	$244M	$206M	$153M	$119M	$55M	$49M	$34M	$48M	$9M	$15M	$8M	$33M	$19M	$26M	$33M	$45M
Cash & Cash Equivalents	$125M	$100M	$75M	$69M	$51M	$68M	$34M	$27M	$18M	$27M	$23M	$15M	$30M	$8M	$14M	$6M	$31M	$17M	$16M	$13M	$9M
Total Liabilities	$133M	$133M	$141M	$128M	$81M	$73M	$71M	$42M	$16M	$32M	$24M	$12M	$12M	$5M	$6M	$21M	$30M	$2M	$3M	$5M	$3M
Total Debt (Short + Long-Term)	$14M	$14M	$9M	$6M	$4M	$3M	$4M	$6M	$0M	$17M	$1M	$0M	$0M	$0M	$0M	$0M	$0M	$1M	$1M	$1M	$2M
Total Shareholders' Equity	$370M	$355M	$292M	$226M	$192M	$170M	$134M	$111M	$102M	$23M	$25M	$22M	$36M	$4M	$10M	($13M)	$3M	$17M	$23M	$28M	$42M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive VCEL viewer.

Other Companies in BIOTECHNOLOGY

KOD · Kodiak Sciences Inc — $2 billion
NUVB · Nuvation Bio Inc — $2 billion
RXRX · Recursion Pharmaceuticals Inc — $2 billion
ZBIO · Zenas BioPharma, Inc. Common Stock — $2 billion
ADMA · ADMA Biologics Inc — $2 billion
AGIO · Agios Pharm — $2 billion
MESO · Mesoblast Ltd — $2 billion
RAPP · Rapport Therapeutics, Inc. Common Stock — $2 billion

← VCEB All “V” companies VCHY →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.